Mindax Limited

MDX

Mindax Ltd. engages in the exploration and development of mineral properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2004-12-08. The Company’s portfolio of projects includes iron ore and gold. Its projects include the Mt Forrest Iron Project, Mt Lucky Gold project and Meekatharra North Project. The Mt Forrest iron project is in the Yilgarn province. The company comprises seven mining leases and is located 600 kilometers (km) from the Port of Geraldton and 165 km from the southbound railway at Menzies and around 648 km from the port at Esperance. The project is a world-scale iron ore resource. The Meekatharra North Project comprises one granted exploration license, E51/1705. The Meekatharra North Project is a gold-mining center in the Murchison Goldfields of Western Australia. The project is located 40 km north of the township of Meekatharra, at the northern end of the Meekatharra Greenstone Belt, in the Murchison Province, Western Australia. Mt Lucky lies within the Mt Margaret Mineral Field of the north-eastern Goldfields of Western Australia.

Melodiol Global Health Limited

ME1

Melodiol Global Health Ltd. develops, registers and commercializes pharmaceutical-grade cannabis and hemp-hemp-derived therapeutic, nutraceutical, and lifestyle products with wide patient and consumer reach for human and animal health. The firm is engaged in developing cannabis and hemp-derived therapeutic-grade nutraceuticals and medical cannabis products with a range of applications in both human and animal health. Its cannabidiol (CBD) plant-based nutraceutical products are non-psychoactive, as they only contain trace amounts of tetrahydrocannabinol (THC). Its product is offered under various brands, including Green Goo, Southern Butter, Good Goo, Ritual, impactive and cannaQIX, among others. The company cultivates and harvests cannabis plants through its subsidiary, Mernova Medicinal Inc. and supplies cannabis retail products throughout Canada. Through its wholly owned, Canada-based psychedelics subsidiary, Halucenex Life Sciences Inc., it is also focused on the development of synthetic and botanical psilocybin treatments for treatment-resistant post-traumatic stress disorder, and other mental health conditions.